Revolution Medicines reported strong Phase III data for daraxonrasib (RASolute 302) in metastatic pancreatic ductal adenocarcinoma, pushing the once-undruggable KRAS space further into the spotlight. In the intent-to-treat population, the company said median overall survival reached 13.2 months versus 6.7 months for standard-of-care chemotherapy, with a hazard ratio of 0.40. Investors reacted sharply to the results, with the stock rising materially over the week following the data release. Jefferies analyst Faisal Khurshid said the disclosed results exceeded expected OS thresholds in an April 13 research note, describing the outcome as “best-case.” Revolution said it is moving with urgency toward global regulatory submissions and expanding development across RAS-addicted cancers.